The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10625 malaria professionals are enjoying the free benefits of MalariaWorld today


Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults

September 15, 2020 - 10:09 -- Open Access
Healy SA, Murphy SC, Duffy PE, et al.
Clin Infect Dis. 2020 Sep 12;71(6):1481-1490

Chemoprophylaxis vaccination with sporozoites (CVac) with chloroquine induces protection against a homologous Plasmodium falciparum sporozoite (PfSPZ) challenge, but whether blood-stage parasite exposure is required for protection remains unclear. Chloroquine suppresses and clears blood-stage parasitemia, while other antimalarial drugs, such as primaquine, act against liver-stage parasites. Here, we evaluated CVac regimens using primaquine and/or chloroquine as the partner drug to discern whether blood-stage parasite exposure impacts protection against homologous controlled human malaria infection.

NOT Open Access | Malaria Disease and Chemoprophylaxis Usage among Israeli Travelers to Endemic Countries

April 13, 2020 - 15:09 -- NOT Open Access
Harel R, Chazan B, Schwartz E
Am J Trop Med Hyg. 2020 Apr 6

Prevention of malaria in travelers to endemic countries is one of the complex challenges of travel medicine. Israel has a widespread culture of travel to developing countries, but information regarding malaria prevention is limited so far. Our study, conducted in Sheba Medical Center, Israel, during the years 2008–2018 examined malaria chemoprophylaxis usage and malaria cases in a large group of Israeli travelers returning from endemic countries with any medical complaint.

The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data

March 2, 2020 - 15:29 -- Open Access
Bretscher MT, Dahal P, Okell LC, et al.
BMC Med. 2020 Feb 25; 18(1):47

The majority of Plasmodium falciparum malaria cases in Africa are treated with the artemisinin combination therapies artemether-lumefantrine (AL) and artesunate-amodiaquine (AS-AQ), with amodiaquine being also widely used as part of seasonal malaria chemoprevention programs combined with sulfadoxine-pyrimethamine. While artemisinin derivatives have a short half-life, lumefantrine and amodiaquine may give rise to differing durations of post-treatment prophylaxis, an important additional benefit to patients in higher transmission areas.

A systematic review of factors affecting adherence to malaria chemoprophylaxis amongst travellers from non-endemic countries

January 15, 2020 - 14:37 -- Open Access
Julian Ahluwalia, Samantha K. Brooks, John Weinman and G. James Rubin
Malaria Journal 2020 19:16, 13 January 202

The aim of this systematic review was to identify predictors of actual or intended adherence with malaria chemoprophylaxis amongst travellers from non-endemic countries visiting endemic countries.

Utilization patterns of malaria chemoprophylaxis among Tanzanian children attending sickle cell clinic in Dar es Salaam tertiary hospitals

December 10, 2019 - 08:03 -- Open Access
Esther J. Ndegeulaya, George M. Bwire, Raphael Z. Sangeda, Doreen Mloka, Faustine Tungaraza, Augustino S. Kahere, Fidelis F. Manyaki, Fatuma F. Felician, Manase Kilonzi, Wigilya P. Mikomangwa, Hamu J. Mlyuka, Alphonce I. Marealle, Ritah Mutagonda, Liberata Mwita and Kennedy D. Mwambete
Malaria Journal 2019 18:393, 3 December 2019

Malaria is among the leading cause of infection in individuals with sickle cell disease (SCD) living in sub-Saharan Africa, including Tanzania. However, after 2005 the standard treatment guidelines (STGs) on malaria chemoprevention for SCD patients were non-existent, and at present no medicine is recommended for SCD patients. Since several anti-malarials have been approved for the treatment of malaria in Tanzania, it is important to establish if there is a continued use of chemoprevention against malaria among SCD children.

NOT Open Access | Atovaquone/proguanil for malaria chemoprophylaxis - Could a difference in susceptibility during hepatic development explain the need to continue drug intake for 7 days post-exposure?

November 26, 2019 - 13:36 -- NOT Open Access
Hanscheid T, Schlagenhauf P, Grobusch MP.
Travel Medicine and Infectious Disease, 21 November 2019, 101527

No abstract available

Failure of atovaquone-proguanil malaria chemoprophylaxis in a traveler to Ghana

February 5, 2015 - 15:44 -- Open Access
Andrea K. Boggild, Rachel Lau, Denis Reynaud, Kevin C. Kain, Marvin Gerson
Travel Medicine and Infectious Disease, Volume 13, Issue 1, January–February 2015, Pages 89-93

We report a case of Plasmodium falciparum malaria in a returned traveler to Ghana who fully adhered to atovaquone-proguanil (Malarone™) chemoprophylaxis daily dosing, yet took the pills on an empty stomach.

Severity of imported malaria: protective effect of taking malaria chemoprophylaxis

August 5, 2013 - 15:17 -- Open Access
Vliegenthart-Jongbloed K, de Mendonça Melo M, van Wolfswinkel ME, Koelewijn R, van Hellemond JJ, van Genderen PJ
Malaria Journal 2013, 12:265 (31 July 2013)

The aim of this study was to assess the impact of use of malaria chemoprophylaxis on clinical features and outcome of imported malaria.

Does public subsidy of the cost of malaria chemoprophylaxis reduce imported malaria? A comparative policy analysis

July 16, 2013 - 15:59 -- Open Access
Neave PE, Taylor S, Behrens RH
Malaria Journal 2013, 12:238 (12 July 2013)

This policy was not implemented in three Primary Care Trusts (PCTs) in London due to concern about the potential increase of imported malaria in their residents, and they maintained the public subsidy.

Subscribe to RSS - chemoprophylaxis